These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

76 related items for PubMed ID: 20120857

  • 21. Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer.
    Sutter AP, Höpfner M, Huether A, Maaser K, Scherübl H.
    Int J Cancer; 2006 Apr 01; 118(7):1814-22. PubMed ID: 16217753
    [Abstract] [Full Text] [Related]

  • 22. Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells.
    Sugimoto T, Bartholomeusz C, Tari AM, Ueno NT.
    Breast Cancer Res; 2007 Apr 01; 9(4):R41. PubMed ID: 17612393
    [Abstract] [Full Text] [Related]

  • 23. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.
    Cancer Res; 2004 Aug 01; 64(15):5355-62. PubMed ID: 15289342
    [Abstract] [Full Text] [Related]

  • 24. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
    Narayanan BA, Reddy BS, Bosland MC, Nargi D, Horton L, Randolph C, Narayanan NK.
    Clin Cancer Res; 2007 Oct 01; 13(19):5965-73. PubMed ID: 17908994
    [Abstract] [Full Text] [Related]

  • 25. Celecoxib induces dose dependent growth inhibition in nasopharyngeal carcinoma cell lines independent of cyclooxygenase-2 expression.
    Chan CM, Ma BB, Wong SC, Chan AT.
    Biomed Pharmacother; 2005 Oct 01; 59 Suppl 2():S268-71. PubMed ID: 16507390
    [Abstract] [Full Text] [Related]

  • 26. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
    Gadgeel SM, Ruckdeschel JC, Heath EI, Heilbrun LK, Venkatramanamoorthy R, Wozniak A.
    J Thorac Oncol; 2007 Apr 01; 2(4):299-305. PubMed ID: 17409801
    [Abstract] [Full Text] [Related]

  • 27. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
    Xie H, Gao L, Chai N, Song J, Wang J, Song Z, Chen C, Pan Y, Zhao L, Sun S, Wu K, Feitelson MA, Liu J, Fan D.
    Mol Carcinog; 2009 Jan 01; 48(1):56-65. PubMed ID: 18506760
    [Abstract] [Full Text] [Related]

  • 28. [Effects of celecoxib combined with fluvastatin on tumor growth and cell apoptosis in a xenograft model of hepatocellular carcinoma].
    Gao J, Li JS, Xu GL, Jia WD, Ma JL, Yu JH, Ge YS.
    Zhonghua Gan Zang Bing Za Zhi; 2010 Dec 01; 18(12):900-4. PubMed ID: 21205474
    [Abstract] [Full Text] [Related]

  • 29. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS, Liu DS, Dai CW, Li RJ.
    Am J Hematol; 2006 Apr 01; 81(4):242-55. PubMed ID: 16550520
    [Abstract] [Full Text] [Related]

  • 30. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
    Gadgeel SM, Ali S, Philip PA, Wozniak A, Sarkar FH.
    Cancer; 2009 May 15; 115(10):2165-76. PubMed ID: 19288574
    [Abstract] [Full Text] [Related]

  • 31. [Effects of EGFR inhibitor AG1478 in combination with celecoxib on the growth of gastric cancer cells].
    Li RK, Qiang O, Liao J, Wang CH.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Jul 15; 41(4):595-9. PubMed ID: 20848776
    [Abstract] [Full Text] [Related]

  • 32. Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer.
    Lanza-Jacoby S, Burd R, Rosato FE, McGuire K, Little J, Nougbilly N, Miller S.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6161-9. PubMed ID: 17062693
    [Abstract] [Full Text] [Related]

  • 33. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt.
    Liu B, Shi ZL, Feng J, Tao HM.
    Cell Biol Int; 2008 May 15; 32(5):494-501. PubMed ID: 18078766
    [Abstract] [Full Text] [Related]

  • 34. Celecoxib-erlotinib combination treatment enhances radiosensitivity in A549 human lung cancer cell.
    Sun J, Liu NB, Zhuang HQ, Zhao LJ, Yuan ZY, Wang P.
    Cancer Biomark; 2017 May 15; 19(1):45-50. PubMed ID: 28282799
    [Abstract] [Full Text] [Related]

  • 35. [Celecoxib increased cellular ATRA sensitivity of human colon cancer cell lines through COX-2-independent mechanisms].
    Liu JP, Wei HB, Zheng ZH, Guo WP, Fang JF.
    Yao Xue Xue Bao; 2009 Dec 15; 44(12):1353-8. PubMed ID: 21351468
    [Abstract] [Full Text] [Related]

  • 36. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
    Lev-Ari S, Strier L, Kazanov D, Madar-Shapiro L, Dvory-Sobol H, Pinchuk I, Marian B, Lichtenberg D, Arber N.
    Clin Cancer Res; 2005 Sep 15; 11(18):6738-44. PubMed ID: 16166455
    [Abstract] [Full Text] [Related]

  • 37. Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s).
    Narayanan BA, Condon MS, Bosland MC, Narayanan NK, Reddy BS.
    Clin Cancer Res; 2003 Aug 15; 9(9):3503-13. PubMed ID: 12960143
    [Abstract] [Full Text] [Related]

  • 38. Cyclooxygenase-2 (COX-2) negatively regulates expression of epidermal growth factor receptor and causes resistance to gefitinib in COX-2-overexpressing cancer cells.
    Kim YM, Park SY, Pyo H.
    Mol Cancer Res; 2009 Aug 15; 7(8):1367-77. PubMed ID: 19671676
    [Abstract] [Full Text] [Related]

  • 39. Simultaneous inhibition of EGFR/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells.
    Valverde A, Peñarando J, Cañas A, López-Sánchez LM, Conde F, Hernández V, Peralbo E, López-Pedrera C, de la Haba-Rodríguez J, Aranda E, Rodríguez-Ariza A.
    PLoS One; 2015 Aug 15; 10(6):e0131363. PubMed ID: 26107817
    [Abstract] [Full Text] [Related]

  • 40. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
    Liu W, Chen Y, Wang W, Keng P, Finkelstein J, Hu D, Liang L, Guo M, Fenton B, Okunieff P, Ding I.
    Am J Clin Oncol; 2003 Aug 15; 26(4):S103-9. PubMed ID: 12902866
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.